Navigation Links
Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2007 Financial Results
Date:10/24/2007

Keryx to Host Investor Conference Call on Thursday, October 25, 2007 at

8:30am EDT

NEW YORK, Oct. 24 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX), a biopharmaceutical company focused on the acquisition, development and commercialization of medically important, novel pharmaceutical products for the treatment of life-threatening diseases, including diabetes and cancer, today announced its results for the third quarter ended September 30, 2007.

At September 30, 2007, the Company had cash, cash equivalents, investment securities, interest receivable and license receivable of $82.7 million, as compared to $125.6 million at December 31, 2006. The nonrefundable license receivable of $12.0 million was received in October 2007 and related to a recent licensing agreement entered into with Japan Tobacco Inc. and Torii Pharmaceutical Co., Ltd.

The net loss for the third quarter ended September 30, 2007 was $19,528,000, or $0.45 per share, compared to a net loss of $17,993,000, or $0.42 per share, for the comparable quarter in 2006, representing an increase in net loss of $1,535,000. The increase in net loss was primarily attributable to a $627,000 increase in research and development expenses related to the Company's Sulonex(TM) (sulodexide) pivotal Phase III and Phase IV clinical program, a $346,000 increase in expenses related to the Company's other clinical compounds, and a $845,000 decrease in interest and other income, offset by a $344,000 decrease in non-cash compensation expense related to stock option and restricted stock grants.

The net loss for the nine months ended September 30, 2007 was $60,801,000, or $1.40 per share, compared to a n
'/>"/>

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Speaker announces business members of IT Task Force
2. Doyle announces technology tax credits for Berbee
3. Doyle announces new energy, global warming policies
4. Doyle announces $80M renewable energy strategy
5. GE announces first installation of Discovery VCT
6. UWM announces winners of RGI awards
7. Third Wave announces two senior management appointments
8. Mirus announces new method for making antibodies
9. Merge announces sofware updates, upcoming acquisition
10. Small Tree announces ethernet solution for Apple Xserv G5
11. TEKLYNX International announces new RFID software
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... Sigma-Aldrich Corporation (NASDAQ: SIAL ... the Hart-Scott-Rodino Antitrust Improvements Act (HSR Act) in ... 2014, thereby completing the U.S. HSR Act antitrust ... the Company by Merck KGaA, Darmstadt, Germany.  ... to closing the transaction, which remains subject to ...
(Date:12/22/2014)... , Dec. 22, 2014   Synthetic ... developer of pathogen-specific therapies for serious infections ... the microbiome, today announced positive topline safety ... clinical trial of SYN-004, the Company,s investigational ... Clostridium difficile (C. difficile) infection, ...
(Date:12/22/2014)... 22, 2014  ( www.competitivehealth.com ) — Competitive Health ... bill review and advocacy service, has signed an agreement ... Savings discount health services marketplace. 63% of ... than they expected to pay. As part of an ... WellCard Savings is pleased to offer medical bill review ...
(Date:12/19/2014)... Hershey, PA (PRWEB) December 19, 2014 ... a leading developer and manufacturer of needle-free injection ... an agreement with Immunomic Therapeutics, Inc. (“ITI”) for ... injection device with its LAMP™ vaccine platform. ... for an exclusive Worldwide license to the Biojector®-2000 ...
Breaking Biology Technology:Acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany, Receives U.S. Antitrust Clearance 2Acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany, Receives U.S. Antitrust Clearance 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 2Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 4Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 5WellCard Savings Announces CoPatient Medical Bill Review Service for Members 2Bioject and Immunomic Therapeutics Enter into an Agreement for License of Needle-Free Technology for LAMP-vax Vaccines 2Bioject and Immunomic Therapeutics Enter into an Agreement for License of Needle-Free Technology for LAMP-vax Vaccines 3
... Therapies to Address the Underlying Cause of Cystic,Fibrosis; ... SOUTH PLAINFIELD, N.J., Aug. 20 New ... that the investigational oral drug,PTC124 demonstrates activity in ... with PTC124 results in statistically significant,improvements in the ...
... Oncothyreon Inc. (Nasdaq:,ONTY) (TSX: ONY) announced today that ... on August 14, 2008 indicating that Oncothyreon does ... The NASDAQ Global Market,because it does not meet ... (i) the market value of Oncothyreon,s common stock ...
... Crystal Research Associates, LLC,announced today that ... on Generex Biotechnology Corporation (Nasdaq: GNBT ... at http://www.crystalra.com ., Generex Biotechnology ... pharmaceutical company that aims to research, develop, ...
Cached Biology Technology:PTC124 Shows Promising Activity in Cystic Fibrosis; Phase 2 Proof-of-Concept Data Published in the Lancet 2PTC124 Shows Promising Activity in Cystic Fibrosis; Phase 2 Proof-of-Concept Data Published in the Lancet 3PTC124 Shows Promising Activity in Cystic Fibrosis; Phase 2 Proof-of-Concept Data Published in the Lancet 4PTC124 Shows Promising Activity in Cystic Fibrosis; Phase 2 Proof-of-Concept Data Published in the Lancet 5Oncothyreon announces receipt of notice of non-compliance with market value of listed securities standard for listing on The NASDAQ Global Market 2Oncothyreon announces receipt of notice of non-compliance with market value of listed securities standard for listing on The NASDAQ Global Market 3Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Generex Biotechnology Corporation 2Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Generex Biotechnology Corporation 3
(Date:12/3/2014)... , Dec. 2, 2014 As part ... readers, Inception Technologies is pleased to announce the release ... for customers to collect the workforce data that they ... that have been left by existing readers. Many such ... interface, connectivity and modern technology. Older models force users ...
(Date:11/21/2014)... 20, 2014 Strict laws against distracted driving ... the North American and European automotive sector towards gesture ... recognition systems that are intuitive and able to retrieve ... industry. New analysis from Frost & ... in Europe and ...
(Date:11/18/2014)... -- The Secure Identity & Biometrics Association (SIBA) and ... formation of The Airport Entry and Exit Working ... Biometric Entry and Exit Solutions Framework for Airports ... BORDERPOL, the international non-profit organization that works directly ... border security, traveler and migration systems. ...
Breaking Biology News(10 mins):Inception Technologies to Release New Biometric Reader 2Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 2Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 3Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 4Identity Management, Document Authentication and Biometric Companies Form "The Airport Entry and Exit Working Group", Releasing the Framework to Help Guide the Department of Homeland Security and Congress Towards Solutions 2Identity Management, Document Authentication and Biometric Companies Form "The Airport Entry and Exit Working Group", Releasing the Framework to Help Guide the Department of Homeland Security and Congress Towards Solutions 3
... Jude Children,s Research Hospital scientists has identified a potential ... retinoblastoma. Their work also settles a scientific debate by ... the developmental pathways at work in the tumor. ... cell, researchers showed that retinoblastoma is a hybrid cell ...
... CAAugust 14, 2011Scientists at the Gladstone Institutes have gained new ... out of balance, can prevent the normal development of stem ... some types of cancer. "The news, being announced in ... , adds to the understanding of the role of stem ...
... New Zealand have identified the direct impact of fishing ... of the endangered native sea lion population. The team,s ... factors, such as disease and identifies resource competition and ... New Zealand sea lion Phocarctos hookeri is the country,s ...
Cached Biology News:Childhood eye tumor made up of hybrid cells with jumbled development 2Childhood eye tumor made up of hybrid cells with jumbled development 3Gladstone scientists offer new insight into the regulation of stem cells and cancer cells 2Gladstone scientists offer new insight into the regulation of stem cells and cancer cells 3Competition with humans responsible for decline of New Zealand's endangered sea lions, study shows 2
GFX PCR DNA,Gel Band Purif,100, 1 EA. Category: Nucleotide Sample Handling....
Full service including gene cloning, protien expression and purification of 1 liter culture....
Superior homology search software - in all the flavours of blast, with increased sensitivity and speed...
Protein 3D structure prediction, via threading. Easy to use....
Biology Products: